JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $45
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $33 to $45.
Login to comment